Tourmaline bio initiates clinical development of tour006 for cardiovascular diseases with first patient dosed in phase 2 tranquility trial

– first patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of tour006 in patients with inflammatory risk and chronic kidney disease – – topline data anticipated in the first half of 2025 with potential to advance tour006 toward phase 3 readiness for atherosclerotic cardiovascular disease (ascvd) and other cardiovascular diseases – – tranquility trial intended to provide evidence of tour006's best-in-class potential for ascvd, including the potential for quarterly subcutaneous dosing – new york, may 16, 2024 (globe newswire) -- tourmaline bio, inc. (tourmaline) (nasdaq: trml), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that the first patient has been dosed in its phase 2 tranquility trial, marking the initiation of its clinical development program for tour006, a long-acting, fully human, anti-il-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease (ascvd) and other cardiovascular diseases. tranquility is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity c-reactive protein (hs-crp) at baseline, and chronic kidney disease (ckd).
TOUR Ratings Summary
TOUR Quant Ranking